Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MEN2312 |
| Synonyms | |
| Therapy Description |
MEN2312 inhibits the histone acetyltransferase KAT6, which potentially results in altered gene expression and decreased proliferation in tumors overexpressing KAT6 (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MEN2312 | MEN-2312|MEN 2312 | MEN2312 inhibits the histone acetyltransferase KAT6, which potentially results in altered gene expression and decreased proliferation in tumors overexpressing KAT6 (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06638307 | Phase I | Elacestrant + MEN2312 MEN2312 | A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | Recruiting | USA | 0 |